1. Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis
- Author
-
Yang, YC, Lu, ML, Rao, JY, Wallerand, H, Cai, L, Cao, W, Pantuck, A, Dalbagni, G, Reuter, V, Figlin, RA, Belldegrun, A, Cordon-Cardo, C, and Zhang, ZF
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Genetics ,Urologic Diseases ,Cancer ,Aetiology ,2.1 Biological and endogenous factors ,Aged ,DNA Mutational Analysis ,Female ,Genes ,p53 ,Humans ,Male ,Middle Aged ,Mutation ,Polymorphism ,Single Nucleotide ,Prognosis ,Receptor ,Fibroblast Growth Factor ,Type 4 ,Survival Analysis ,Survival Rate ,Urinary Bladder Neoplasms ,bladder cancer ,single nucleotide polymorphism ,fibroblast growth factor receptor 4 ,prognosis ,TP53 mutation ,Public Health and Health Services ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
The impact of the fibroblast growth factor receptor 4 (FGFR4) Gly388Arg polymorphism on bladder cancer is unknown. We found no clear correlations between the FGFR4 genotype and risk of bladder cancer or pathological parameters. Neither the polymorphism nor TP53 mutation status was an independent predictor of prognosis, but they might act jointly on the disease-specific survival of patients.
- Published
- 2006